By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • CEU Executive MBA - Vienna On-Site & Online Open Day

    11.03.2021/ 06:00pm (CET), Vienna, Online

  • ABA's Open Day 2021: Austria - Your ICT and Innovation Hub in the Heart of Europe

    11 March 2021/ 09.00am + 05.00 pm, Online Conference

Austria Map

Find the perfect location for your company

Reliability and expertise in the country and in the company are the convincing factors in selecting a business location. We can be justifiably proud but can still become even more attractive. This is something Austria should increasingly work on in the future!

Pfizer

Logo
More testimonials

news from the business location Austria

OMV and Kommunalkredit invest in the production of green hydrogen

The Austrian oil and gas company OMV and Kommunalkredit Austria AG (Kommunalkredit) have announced a joint investment in the construction of Austria’s largest electrolysis plant to be located in the OMV Schwechat Refinery.

5G Technology – boosting post-COVID economy in Austria

The worldwide experience from the first 5G FWA implementations replacing in difficult areas the costly construction of cable networks in such conditions is urgently observed in many regions of the world, also in Europe, where service providers count on their implementation.

More news All blog posts